Vitrolife AB (publ) held its Capital Markets Day on September 20, 2016 at its head office in Gothenburg. Approximately 50 analysts, investors and shareholders attended.

The program contained an update of operative and financial developments in the Group by the CEO, Thomas Axelsson. Dr. Niels B. Ramsing, Business Unit Time-lapse, Strategic Product Development, presented time-lapse within IVF and Vitrolife’s most recent launch, EmbryoScope+. Dr. Paul Gassner, Business Unit Director ART Equipment, presented Vitrolife’s new business unit ART Equipment, a new acquisition from MTG/Octax. There was also an opportunity to visit the production facility and to see how some of the most important products are used.

Vitrolife

Thomas Axelsson started with a presentation of Vitrolife, our strategies and plans for the future, and the acquisition of MTG/Octax. The acquisition broadens the product offering to customers in a market segment with rapid growth.

 

 
 

 

Time-lapse and EmbryoScope+

Niels B. Ramsing presented developments in the field of time-lapse and the clinical significance of time-lapse in IVF. Niels also presented Vitrolife's most recent launch within the area, EmbryoScope+. The audience showed great interest in EmbryoScope+ and had many questions about time-lapse in general.


Great interest in Vitrolife's acquisition of MTG/Octax

Paul Gassner introduced the company and their main products, where the focus was on microlasers and automated quality control devices for ART. Paul also explained how these products complement Vitrolife's product portfolio and fit in with today's market trends within biopsy.


Product presentations most appreciated

All participants were able to learn more about Vitrolife's products. This year focus was on EmbryoScope+, biopsy and products from our Media and Disposable Devices business units. The visitors were also given the opportunity to see our production facility. There was great interest in all stations and our Product Managers had a lot of questions to answer regarding their product.

 


Dr. Klaus Rink demonstrates Vitrolife's most recent addition to the product portfolio, MTG/Octax laser system. This product aroused great interest on the part of the visitors.

 


Dr. Niels B. Ramsing shows Vitrolife's most recent launch, EmbryoScope+, and its work flow.

 

Our Product Managers in the Media and Disposable Devices Business Units received many interesting questions from the visitors. 

 
Satisfied visitors will continue to invest

Many of the participants came from banks and investment companies, but there were also private investors, who were also very pleased with the Capital Markets Day.